Warfarin vs aspirin for symptomatic intracranial stenosis: subgroup analyses from WASID.
The WASID trial showed no advantage of warfarin over aspirin for preventing the primary endpoint of ischemic stroke, brain hemorrhage, or vascular death. In analyses of selected subgroups, there was no definite benefit from warfarin. Warfarin reduced the risk of the primary endpoint among patients with basilar artery stenosis, but there was no reduction in stroke in the basilar artery territory or benefit for vertebral artery stenosis or posterior circulation disease in general.
Kasner
S E
SE
Department of Neurology, University of Pennsylvania Medical Center, Philadelphia, PA, USA. kasner@mail.med.upenn.edu
Lynn
M J
MJ
Chimowitz
M I
MI
Frankel
M R
MR
Howlett-Smith
H
H
Hertzberg
V S
VS
Chaturvedi
S
S
Levine
S R
SR
Stern
B J
BJ
Benesch
C G
CG
Jovin
T G
TG
Sila
C A
CA
Romano
J G
JG
D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use*; D002539:Cerebral Arterial Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*; D003251:Constriction, Pathologic / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology; D014859:Warfarin / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000925:Anticoagulants; D014859:Warfarin; D001241:Aspirin